Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer.
about
Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancerManagement of relapsed ovarian cancer: a reviewImmune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?Pegylated liposomal doxorubicin in the management of ovarian cancer: a systematic review and metaanalysis of randomized trialsCan nanomedicines kill cancer stem cells?The potential of polymeric micelles in the context of glioblastoma therapy.Advanced ovarian cancer: what should be the standard of care?Update on immune checkpoint inhibitors in gynecological cancersClinical Translation of Nanomedicine.Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer.Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.Development of nanoscale approaches for ovarian cancer therapeutics and diagnosticsEvaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.Optimal chemotherapy treatment for women with recurrent ovarian cancerSafety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial.A phase I study to characterize the safety, tolerability, and pharmacokinetics of topotecan at 4 mg/m2 administered weekly as a 30-minute intravenous infusion in patients with cancer.A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study.New developments in treatment of ovarian carcinoma: focus on trabectedinPhase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer.Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma.Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients.A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy.The role of pegylated liposomal doxorubicin in ovarian cancer: a meta-analysis of randomized clinical trialsTemsirolimus and pegylated liposomal doxorubicin (PLD) combination therapy in breast, endometrial, and ovarian cancer: phase Ib results and prediction of clinical outcome with FDG-PET/CT.Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma.HLA-G expression is an independent predictor for improved survival in high grade ovarian carcinomasPhase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancerAdjusting for misclassification in a stratified biomarker clinical trial.Pegylated liposomal doxorubicin in the management of ovarian cancerPhase I trial of ixabepilone plus pegylated liposomal doxorubicin in patients with adenocarcinoma of breast or ovary.A threshold sample-enrichment approach in a clinical trial with heterogeneous subpopulations.Major clinical research advances in gynecologic cancer in 2010NANOMATERIALS FOR PROTEIN MEDIATED THERAPY AND DELIVERY.Circumventing tumor resistance to chemotherapy by nanotechnologyEmerging role of pemetrexed in ovarian cancer.Oral squamous cell carcinoma in a patient treated with long-term pegylated liposomal doxorubicin for recurrent ovarian cancer.Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancerOncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer.Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer.Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin
P2860
Q24201282-1545B643-CC42-47E4-AD35-38AFB0AA996CQ26741755-45CB41CD-A2A1-4850-99CA-882ABBB37D88Q26742047-0E73D7FB-E8B8-4A73-8578-92A728ED0AC2Q26858830-1F0E3964-E27D-4684-9428-3117796B150FQ27022017-BCB8D4C9-8662-4BA2-A0FA-EC4ED03EECF5Q27693205-D53A1D35-A539-40AA-8AB0-B85D0265DB6EQ27852053-6C12EB33-055D-414C-992F-4DCA50B0E1CDQ28076497-32D195D7-3C43-46E1-A694-350DD3A66858Q30355939-D10F84F4-D1C4-4640-9122-4FBD7B9CF702Q30358635-7B9CEC00-C1A1-4984-AA69-A07772F37E65Q30366990-03F27F4B-EDF3-4B14-A929-DBCAFC0E64E0Q30421664-65398A2F-7D4F-44BC-9379-7E3788DBBDF7Q30436714-87FD28DA-B2BD-49B9-8832-3E8374C86AF3Q33302771-4AC0C82F-FD64-4A2A-92BC-59E8189CF20EQ33372127-03DE678B-FA86-4BA1-AA33-2DEDA165C79CQ33386523-C2BFC53D-528D-478A-B6D8-C6348FBF543FQ33387755-2F4D0DFE-1FAD-440E-B442-A210773F17D2Q33393429-09896A99-1017-4B08-B534-BC8C6FB8BE11Q33393879-9E02757B-298C-4C13-A680-F97FC540B927Q33395016-8DA330E3-AB3B-43D8-B828-62C43BACF0C3Q33395587-14919341-2439-4A19-AF38-6491CE89759AQ33397131-093F17D2-D115-4C87-BEB2-EEA0F492D724Q33409319-839B3BCE-CF51-4561-B54E-41C0D8B2C9CFQ33413585-98C6D7A3-68F7-4A33-96FE-8CEA0C642A9EQ33415076-E33CE68D-BD15-47F4-9BE5-3BA35DD2256EQ33758727-27FDABFA-C3D0-4346-A890-D783B19CF0A5Q33776904-3C644BD6-FF24-44D5-95BE-5AE6B719341CQ33934232-090B0AB4-48A9-43AB-95C2-C4CF8CA71C67Q34187661-BD40BBBB-2FB7-4F00-BD22-7EABAF515FC0Q34307937-35602909-0196-43CC-A55D-A521C2D8449EQ34370382-303EF71B-8A91-41EB-99DF-D7BA157B1733Q34517694-460BCEDB-A9B9-4113-8E1F-593FBA56D2F3Q34534023-96CC0174-32A2-4EE8-91AF-B28B0284D56DQ34618357-F0FF2D54-8458-40FE-AC77-B17067551980Q35015611-CF1C05B4-8397-457C-8D8C-0D914F0FEC9DQ35015808-CD3647A2-1919-4871-AC64-DEAB7C73A435Q35114915-F0A7FB49-7248-456B-AEB3-385872DDE917Q35226511-9B6A5A5E-0EF8-40D0-94AE-CB00C89BE0EDQ35527133-45FEE8C7-7099-4EFE-80C3-61477694216EQ35674891-CDECE888-BC3F-425B-B97D-5882BD954E2F
P2860
Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Long-term survival advantage f ...... ory epithelial ovarian cancer.
@en
Long-term survival advantage f ...... ory epithelial ovarian cancer.
@nl
type
label
Long-term survival advantage f ...... ory epithelial ovarian cancer.
@en
Long-term survival advantage f ...... ory epithelial ovarian cancer.
@nl
prefLabel
Long-term survival advantage f ...... ory epithelial ovarian cancer.
@en
Long-term survival advantage f ...... ory epithelial ovarian cancer.
@nl
P2093
P1433
P1476
Long-term survival advantage f ...... ory epithelial ovarian cancer.
@en
P2093
Alan N Gordon
Doxil Study 30-49 Investigators
Margaret Tonda
Steven Sun
Wayne Rackoff
P356
10.1016/J.YGYNO.2004.07.011
P407
P577
2004-10-01T00:00:00Z